New Delhi: A potential COVID-19 vaccine indigenously developed by the Ahmedabad-based Zydus Cadila Healthcare Ltd has got the nod from the Drugs Controller General of India (DCGI) for human clinical trials, according to a government source.
The approval process was fast-tracked following recommendation by the subject expert committee on COVID-19, considering the emergency and unmet medical need during the pandemic.
“DCGI Dr VG Somani has given approval for the phase I and II clinical trials (on humans) of the potential novel coronavirus vaccine developed by Zydus Cadila Healthcare Ltd, Thursday after its animal studies were found to be successful,” an official source in the know of the developments said Friday.
The assent for human trials was given after the company submitted data of clinical trial on animals to the DCGI, in which the vaccine candidate was found to be successful with respect to safety and immunogenicity, the source said.
The company is likely to start enrolment of subjects soon. “The phase I and II trials will take around three months to be completed,” the source said.
The country’s ‘first’ indigenous COVID-19 vaccine candidate ‘Covaxin’, developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV), had recently got the nod for human clinical trials from the DCGI.
